skip to Main Content
March 17, 2020 1:00 - 1:45 PM ET

No sPCMA, No Worries … We’ve Got Part D Covered

  • This page as PDF


Just because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.

Our experts engaged in a conversation about the outlook for the Part D program and issues to watch during the 2021 bid/contracting cycle and beyond. Our panelists explored the potential implications of a preferred specialty tier on 2021 and 2022 formularies, the future of Part D benefit redesign, and some key impacts across different types of Part D plans.

Our panelists also answered questions from the audience.


Kelly Brantley , Practice Director, Policy

Kelly Brantley co-leads the Policy Practice.

Miryam Frieder , Practice Director, Policy

Miryam Frieder co-leads the Policy Practice.

Michael Schneider , Principal

Mike Schneider is an experienced health care executive with over 20 years of experience in pharmaceutical manufacturer, pharmacy benefit manager, and payer side of health care.

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Drug Pricing
Please enter your email address to be notified when new Drug Pricing insights are published.

Back To Top